March 17, 2015
Swiss-based Actelion Ltd. announced on March 15 that selexipag significantly reduced the risk of morbidity/mortality events by 40% in patients with pulmonary arterial hypertension (PAH) against placebo in the multinational PIII GRIPHON study. The PIII study, a double-blind, placebo-controlled, event-driven...read more